Form D · Biotechnology
Acrivon Therapeutics, Inc.
Watertown, MA · CIK 0001781174
Offering snapshot reported Nov 23, 2021 · SEC filing
- Reported sold
- $100M Offering amount: $100M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 9, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 23, 2021 | Initial | $99,999,974 | No comparison | 13 | SEC filing |
| Feb 12, 2021 | Initial | $15,500,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-422273
Source: Form D, filed Nov 23, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Blume Jensen | Director, Executive |
| Marcin Czernik | Director |
| Eric Devroe | Executive |
| Derek Di Rocco | Director |
| Erick Gamelin | Executive |
| Kristina Masson | Director, Executive |
| Sharon Shacham | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
480 Arsenal Way Suite 100
Watertown, MA, 02472
Watertown, MA, 02472